|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
2,6-dihydroxyanthraquinone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:19269596 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Alb |
albumin |
affects binding |
ISO |
2,6-dihydroxyanthraquinone binds to ALB protein |
CTD |
PMID:16404478 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
2,6-dihydroxyanthraquinone results in increased expression of CYP1A1 mRNA |
CTD |
PMID:11502733 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
2,6-dihydroxyanthraquinone results in increased expression of CYP1B1 mRNA |
CTD |
PMID:11502733 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 2,6-dihydroxyanthraquinone |
CTD |
PMID:12756209 PMID:14557274 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 2,6-dihydroxyanthraquinone |
CTD |
PMID:14557274 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
dibenzoylmethane results in increased expression of ABCG2 protein |
CTD |
PMID:17077187 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[dibenzoylmethane co-treated with sulforaphane] results in decreased phosphorylation of AKT1 protein dibenzoylmethane results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:17942926 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
ISO |
dibenzoylmethane results in increased expression of BAD protein ODC1 protein inhibits the reaction [dibenzoylmethane results in increased expression of BAD protein] |
CTD |
PMID:21523861 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
dibenzoylmethane results in increased expression of BAX protein |
CTD |
PMID:17942926 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
dibenzoylmethane inhibits the reaction [ESR1 protein binds to BCL2 enhancer]; dibenzoylmethane inhibits the reaction [Estradiol results in increased expression of BCL2 mRNA] |
CTD |
PMID:16051634 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
ODC1 protein inhibits the reaction [dibenzoylmethane results in increased activity of CASP9 protein] |
CTD |
PMID:21523861 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions increases expression |
ISO |
[sulforaphane co-treated with dibenzoylmethane] results in increased expression of CBR3 mRNA dibenzoylmethane results in increased expression of CBR3 mRNA |
CTD |
PMID:17942926 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
dibenzoylmethane results in decreased expression of CCND1 protein |
CTD |
PMID:17942926 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
dibenzoylmethane results in decreased expression of CDKN1A protein |
CTD |
PMID:17942926 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Clu |
clusterin |
decreases expression multiple interactions |
ISO |
dibenzoylmethane results in decreased expression of CLU mRNA [sulforaphane co-treated with dibenzoylmethane] results in decreased expression of CLU mRNA |
CTD |
PMID:17942926 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases activity multiple interactions increases expression |
ISO |
dibenzoylmethane results in increased activity of EPHX1 protein [sulforaphane co-treated with dibenzoylmethane] results in increased expression of EPHX1 mRNA dibenzoylmethane results in increased expression of EPHX1 mRNA |
CTD |
PMID:3621371 PMID:17942926 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
dibenzoylmethane inhibits the reaction [ESR1 protein binds to BCL2 enhancer]; dibenzoylmethane inhibits the reaction [ESR1 protein binds to MYC enhancer]; dibenzoylmethane inhibits the reaction [ESR1 protein binds to TERT enhancer] |
CTD |
PMID:16051634 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
dibenzoylmethane results in increased expression of GCLC mRNA [sulforaphane co-treated with dibenzoylmethane] results in increased expression of GCLC mRNA |
CTD |
PMID:17942926 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions increases expression |
ISO |
[sulforaphane co-treated with dibenzoylmethane] results in increased expression of GSTM1 mRNA dibenzoylmethane results in increased expression of GSTM1 mRNA |
CTD |
PMID:17942926 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions increases expression |
ISO |
[sulforaphane co-treated with dibenzoylmethane] results in increased expression of GSTM3 mRNA dibenzoylmethane results in increased expression of GSTM3 mRNA |
CTD |
PMID:17942926 |
|
NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
dibenzoylmethane inhibits the reaction [Estradiol results in increased expression of HRAS mRNA] |
CTD |
PMID:16051634 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
dibenzoylmethane inhibits the reaction [ESR1 protein binds to MYC enhancer] |
CTD |
PMID:16051634 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases response to substance |
ISO |
ODC1 protein inhibits the reaction [dibenzoylmethane results in increased abundance of Reactive Oxygen Species]; ODC1 protein inhibits the reaction [dibenzoylmethane results in increased activity of CASP9 protein]; ODC1 protein inhibits the reaction [dibenzoylmethane results in increased expression of BAD protein] ODC1 protein results in decreased susceptibility to dibenzoylmethane |
CTD |
PMID:21523861 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
ISO |
[sulforaphane co-treated with dibenzoylmethane] results in increased expression of PTGR1 mRNA |
CTD |
PMID:17942926 |
|
NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
dibenzoylmethane results in decreased expression of PTGS2 protein |
CTD |
PMID:17942926 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
dibenzoylmethane inhibits the reaction [ESR1 protein binds to TERT enhancer]; dibenzoylmethane inhibits the reaction [Estradiol results in increased expression of TERT mRNA] |
CTD |
PMID:16051634 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:29,637,506...29,659,561
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
oltipraz results in decreased expression of ABCB11 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO EXP |
oltipraz results in increased expression of ABCB1 mRNA oltipraz results in increased expression of ABCB1A mRNA |
CTD |
PMID:16837569 PMID:18418891 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
EXP |
oltipraz results in increased expression of ABCB1B mRNA |
CTD |
PMID:18418891 |
|
NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC1 protein |
CTD |
PMID:18032408 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression |
ISO EXP |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA oltipraz results in increased expression of ABCC2 mRNA oltipraz results in increased expression of ABCC2 mRNA; oltipraz results in increased expression of ABCC2 protein |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:18032408 PMID:25752797 PMID:34678219 More...
|
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
EXP ISO |
[oltipraz results in increased expression of ABCC3 protein] which affects the export of Acetaminophen metabolite oltipraz results in increased expression of ABCC3 mRNA oltipraz results in increased expression of ABCC3 mRNA; oltipraz results in increased expression of ABCC3 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA] |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:18418891 PMID:22496397 PMID:30114225 More...
|
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions increases expression |
ISO EXP |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA] oltipraz promotes the reaction [ABCC4 protein results in increased transport of Arsenic] oltipraz results in increased expression of ABCC4 mRNA; oltipraz results in increased expression of ABCC4 protein |
CTD |
PMID:15833929 PMID:18032408 PMID:18418891 PMID:20395535 PMID:22496397 PMID:25752797 More...
|
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions increases expression |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA oltipraz results in increased expression of ABCC5 mRNA |
CTD |
PMID:15833929 PMID:18032408 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA oltipraz results in increased expression of ABCC6 mRNA |
CTD |
PMID:15833929 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions increases activity |
ISO |
oltipraz results in increased expression of ABCG2 mRNA oltipraz promotes the reaction [ABCG2 protein results in increased transport of Benzo(a)pyrene metabolite] oltipraz results in increased activity of ABCG2 protein |
CTD |
PMID:15917307 PMID:16837569 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP ISO |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]] |
CTD |
PMID:29211853 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP ISO |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]] |
CTD |
PMID:29211853 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO EXP |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA] oltipraz results in increased activity of AHR protein |
CTD |
PMID:11959854 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases activity |
EXP |
oltipraz results in increased activity of AKR7A3 protein |
CTD |
PMID:9328168 |
|
NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
oltipraz results in decreased expression of ALB mRNA |
CTD |
PMID:9395210 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA] |
CTD |
PMID:17998271 PMID:22496397 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA oltipraz inhibits the reaction [Acetaminophen results in increased expression of BAX protein] |
CTD |
PMID:19433268 PMID:33959992 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein] |
CTD |
PMID:33959992 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
[Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]; oltipraz results in increased localization of and results in increased activity of CEBPB protein |
CTD |
PMID:12509401 PMID:15319326 PMID:15870285 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES1 mRNA NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA] |
CTD |
PMID:30114225 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES2C mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA] |
CTD |
PMID:22429928 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects metabolic processing decreases activity increases expression affects activity |
EXP ISO |
oltipraz results in increased expression of and results in increased activity of CYP1A1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]; 2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; oltipraz results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA] CYP1A1 protein affects the metabolism of oltipraz oltipraz metabolite results in decreased activity of CYP1A1 protein oltipraz results in increased expression of CYP1A1 mRNA; oltipraz results in increased expression of CYP1A1 protein oltipraz affects the activity of CYP1A1 protein |
CTD |
PMID:10775323 PMID:11959854 PMID:15831204 PMID:15890477 PMID:15920769 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions decreases activity affects metabolic processing increases activity |
EXP ISO |
oltipraz results in increased expression of CYP1A2 mRNA oltipraz inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3,4-dimethylimidazo(4,5-f)quinoline] oltipraz metabolite results in decreased activity of CYP1A2 protein; oltipraz results in decreased activity of CYP1A2 protein CYP1A2 protein affects the metabolism of oltipraz oltipraz results in increased activity of CYP1A2 protein NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:8625305 PMID:10775323 PMID:15831204 PMID:15920769 PMID:22496397 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity increases expression affects activity |
ISO |
oltipraz metabolite results in decreased activity of CYP1B1 protein oltipraz results in increased expression of CYP1B1 mRNA oltipraz affects the activity of CYP1B1 protein |
CTD |
PMID:10775323 PMID:15890477 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects metabolic processing increases expression |
EXP |
CYP2B1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP2B1 mRNA; oltipraz results in increased expression of CYP2B1 protein |
CTD |
PMID:15831204 PMID:15920769 PMID:18418891 |
|
NCBI chr 1:90,646,098...90,669,762
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects metabolic processing increases expression |
EXP |
CYP2B2 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP2B2 mRNA; oltipraz results in increased expression of CYP2B2 protein |
CTD |
PMID:15831204 PMID:15920769 PMID:18418891 |
|
NCBI chr 1:90,722,243...90,736,272
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity increases expression |
ISO |
oltipraz results in decreased activity of CYP2B6 protein oltipraz results in increased expression of CYP2B6 mRNA; oltipraz results in increased expression of CYP2B6 protein oltipraz results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17627975 PMID:19833192 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
EXP |
CYP2C11 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2D1 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 7:115,789,026...115,793,430
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects activity |
ISO |
oltipraz affects the activity of CYP2E1 protein |
CTD |
PMID:10775323 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing decreases activity affects activity |
EXP ISO |
CYP3A2 protein affects the metabolism of oltipraz oltipraz metabolite results in decreased activity of CYP3A4 protein; oltipraz results in decreased activity of CYP3A4 protein oltipraz affects the activity of CYP3A4 protein |
CTD |
PMID:10775323 PMID:15831204 PMID:15920769 PMID:19833192 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects metabolic processing increases expression |
EXP |
CYP3A23-3A1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:15831204 PMID:15920769 PMID:18418891 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
oltipraz results in increased expression of EPHX1 mRNA |
CTD |
PMID:18418891 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in increased activity of GOT1 protein] |
CTD |
PMID:33959992 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:33959992 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in decreased activity of GPX3 protein] |
CTD |
PMID:33959992 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in decreased expression of and results in increased secretion of GSTA1 protein]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 protein] |
CTD |
PMID:31385618 PMID:33959992 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
EXP ISO |
oltipraz results in increased expression of GSTA2 mRNA; oltipraz results in increased expression of GSTA2 protein 2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter] |
CTD |
PMID:9203627 PMID:11309284 PMID:12242683 PMID:12509401 PMID:15155840 PMID:15319326 PMID:15870285 More...
|
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
EXP |
oltipraz results in increased expression of GSTA3 mRNA; oltipraz results in increased expression of GSTA3 protein |
CTD |
PMID:9203627 PMID:9794803 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases activity multiple interactions increases expression |
EXP ISO |
oltipraz results in increased activity of GSTA5 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA] oltipraz results in increased expression of GSTA1 mRNA; oltipraz results in increased expression of GSTA1 protein oltipraz results in increased expression of GSTA5 mRNA; oltipraz results in increased expression of GSTA5 protein |
CTD |
PMID:8051171 PMID:8625305 PMID:9203627 PMID:9328168 PMID:11309284 PMID:22496397 More...
|
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression multiple interactions |
EXP ISO |
oltipraz results in increased expression of GSTM1 mRNA [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA] |
CTD |
PMID:9203627 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:198,356,114...198,373,487
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of GSTM3 mRNA [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA] oltipraz results in increased expression of GSTM3 protein |
CTD |
PMID:9794803 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of GSTP1 mRNA oltipraz results in increased expression of and results in increased activity of GSTP1 protein oltipraz results in increased expression of GSTP1 protein |
CTD |
PMID:9794803 PMID:15374950 PMID:16950796 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects localization increases expression |
EXP |
oltipraz affects the localization of GSTT1 protein oltipraz results in increased expression of GSTT1 protein |
CTD |
PMID:9794803 PMID:9855024 PMID:10413528 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hnf1a |
HNF1 homeobox A |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A mRNA]; oltipraz inhibits the reaction [Acetaminophen results in decreased expression of HNF1A protein] |
CTD |
PMID:31385618 PMID:33959992 |
|
NCBI chr12:47,299,171...47,333,457
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
oltipraz results in decreased expression of IVL protein |
CTD |
PMID:10769631 |
|
NCBI chr 2:180,842,307...180,854,646
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in increased phosphorylation of JUN protein] |
CTD |
PMID:33959992 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:33959992 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO EXP |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr 1:50,428,064...50,459,537
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of MCL1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of MGMT mRNA oltipraz results in increased expression of and results in increased activity of MGMT protein |
CTD |
PMID:16950796 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA oltipraz results in increased expression of MGST3 mRNA |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr13:82,059,480...82,080,418
Ensembl chr13:79,526,541...79,547,411
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity affects activity affects response to substance multiple interactions |
ISO EXP |
oltipraz results in increased activity of NFE2L2 protein oltipraz affects the activity of NFE2L2 protein NFE2L2 protein affects the susceptibility to oltipraz [oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B35 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES1G mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of SULT3A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT1A6A mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B36 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz binds to and results in increased activity of NFE2L2 protein; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]] |
CTD |
PMID:11309284 PMID:15833929 PMID:15919853 PMID:19150646 PMID:20086057 PMID:22429928 PMID:22496397 PMID:25752797 PMID:29211853 PMID:30114225 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NQO1 mRNA] oltipraz metabolite results in increased expression of NQO1 protein; oltipraz results in increased expression of NQO1 mRNA; oltipraz results in increased expression of NQO1 protein oltipraz results in increased activity of NQO1 protein oltipraz promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] |
CTD |
PMID:11309284 PMID:12407167 PMID:15919853 PMID:17627975 PMID:18418891 PMID:18488193 PMID:19144771 PMID:19785463 PMID:22496397 PMID:28959534 PMID:30114225 More...
|
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein] |
CTD |
PMID:19433268 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
oltipraz results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:15919853 |
|
NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Acetaminophen results in decreased activity of SOD1 protein] |
CTD |
PMID:33959992 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
oltipraz results in increased expression of SOD2 mRNA |
CTD |
PMID:9395210 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
oltipraz results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16451816 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Doxorubicin results in decreased expression of UCP2 protein] |
CTD |
PMID:29061315 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT1A1 mRNA oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A7 mRNA] |
CTD |
PMID:15374950 PMID:19144771 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases expression |
ISO |
oltipraz results in increased expression of UGT1A5 mRNA |
CTD |
PMID:19144771 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions increases expression |
ISO EXP |
oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A6 mRNA] oltipraz results in increased expression of UGT1A6 mRNA |
CTD |
PMID:15374950 PMID:18418891 PMID:19144771 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2a3 |
UDP glucuronosyltransferase family 2 member A3 |
decreases expression |
ISO |
oltipraz results in decreased expression of UGT2A3 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr14:20,572,793...20,590,795
Ensembl chr14:20,572,808...20,590,729
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases expression multiple interactions increases expression |
ISO EXP |
oltipraz results in decreased expression of UGT2B1 mRNA [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA oltipraz results in increased expression of UGT2B1 mRNA |
CTD |
PMID:18418891 PMID:19144771 PMID:22496397 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT2B34 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA] |
CTD |
PMID:22496397 |
|
NCBI chr14:21,251,535...21,274,451
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 2-vanillin |
CTD |
PMID:15117964 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|